# CEBPA Mutation by PCR

Order Name: **CEBPA PCR**
Test Number: 9616990
Revision Date: 01/24/2025

| TEST NAME | METHODOLOGY | LOINC CODE |
|---|---|---|
| **CEBPA Mutation by PCR** | Polymerase Chain Reaction | |

## SPECIMEN REQUIREMENTS

| Specimen | Specimen Volume (min) | Specimen Type | Specimen Container | Transport Environment |
|---|---|---|---|---|
| **Preferred** | **5 mL (3 mL)** | **Whole Blood** | **EDTA (Lavender Top)** | **Room Temperature** |
| **Alternate 1** | **5 mL (3 mL)** | **Whole Blood** | **Sodium Heparin (Green Top / No-Gel)** | **Room Temperature** |
| **Alternate 2** | **2 mL (1 mL)** | **Bone Marrow** | **EDTA (Lavender Top)** | **Room Temperature** |
| **Alternate 3** | **2mL (1mL)** | **Bone Marrow** | **Sodium Heparin (Green Top / No-Gel)** | **Room Temperature** |

**Instructions**

**Specimen**: 5mL(3mL) Whole Blood or 2mL (1mL) Bone Marrow
**Container**: Lavender-top (EDTA) tube, green-top (sodium heparin) tube
**Collection**: Indicate date and time of collection on the test request form. Submit specimen at room temperature ASAP, Keep at room temperature! (DO NOT FREEZE). Frozen samples will be rejected.
**Storage Instructions**: Maintain specimen at room temperature. If specimen is to be stored prior to shipment, store at 2°C to 8°C.
**Cause for Rejection**: Specimen does not meet all of the above criteria for sample type, container, minimum volume, collection and storage; unsuitable specimens include but are not limited to: frozen whole blood or marrow; a leaking tube; clotted blood or marrow; a grossly hemolyzed specimen or otherwise visibly degraded; specimen suspected of being contaminated by another specimen; specimen contains specific foreign material.

## GENERAL INFORMATION

| | |
|---|---|
| **Testing Schedule** | Mon- Fri |
| **Expected TAT** | 12-14 Days from set up. |
| **Clinical Use** | Determine prognosis in cytogenetically normal acute myelogenous leukemia (CN-AML<br>The CEBPA (CCAAT/enhancer binding protein ) gene encodes a transcription factor important for granulocyte differentiation. CEBPA mutations are found in 6% to 15% of de novo acute myeloid leukemia (AML) and in 15% to 18% of AML with normal karyotypes. CEBPA mutations are associated with favorable prognosis in the absence of associated cytogenetic abnormalities and FLT3 internal duplication (FLT3-ITD). Germline CEBPA mutations are a cause of nonsyndromic, familial AML. |
| **Performing Labcorp Test Code** | 489170 |
| **CPT Code(s)** | 81218 |
| **Lab Section** | Reference Lab |